NUVB
NYSE Nuvation Bio, Inc. Class A$5.14 ↑ +0.00 (+0.00%) Trading Up from the previous close of $5.14, $0.52 below the day’s high of $5.66
- YTD change
- -42.63%
- vs 20-day SMA
- -14.50%
- vs 200-day SMA
- -11.29%
Price ranges
Price & Performance
+0.69 (+15.51%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 66.3% away from all-time highs of $15.23
- NUVB is down 43% since the beginning of the year
- NUVB is up 39% over the past 12 months
- NUVB is down 26% over the past 1 month
- 23% of all NUVB investors are betting against NUVB
- Number of investors short NUVB has gone up 7% versus last month
NUVB reads poor: price sits below both the 20- and 200-day averages, short interest is rising month over month, the 12-month move is +38.5%.
- Previous minute
- +$0.00
- Last hour
- -$0.06
- Last 5 days
- -10.30%
- vs 8-day SMA
- -9.94%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. The company was founded by David Hung on March 20, 2018 and is headquartered in New York, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.